Citadel Advisors
MNOV icon

Citadel Advisors’s MediciNova MNOV Stock Holding History

Citadel Advisors’s Portfolio MNOV Stock Details MNOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,000
Closed -$12.6K – 15060
2024
Q3 		$12.6K Buy
6,000
+2,200
+58% +$3.25K ﹤0.01% 13099
2024
Q2 		$5.47K Buy
3,800
+2,800
+280% +$3.92K ﹤0.01% 13400
2024
Q1 		$1.45K Buy
+1,000
New +$1.42K ﹤0.01% 14128
2023
Q3 		– Sell
-2,800
Closed -$6.44K – 14794
2023
Q2 		$6.44K Buy
2,800
+1,300
+87% +$2.87K ﹤0.01% 13425
2023
Q1 		$3.24K Buy
+1,500
New +$3.44K ﹤0.01% 14057
2021
Q3 		– Sell
-20,900
Closed -$89K – 14342
2021
Q2 		$89K Sell
20,900
-5,300
-20% -$22.8K ﹤0.01% 13008
2021
Q1 		$132K Buy
+26,200
New +$152K ﹤0.01% 12186
2020
Q4 		– Sell
-40,800
Closed -$214K – 11286
2020
Q3 		$214K Buy
+40,800
New +$235K ﹤0.01% 8701
2020
Q1 		– Sell
-18,000
Closed -$121K – 9950
2019
Q4 		$121K Buy
+18,000
New +$135K ﹤0.01% 8471

Other funds holding MNOV

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citadel Advisors's MNOV Position: Q1 2026 in Review

Citadel Advisors sold out of MediciNova (MNOV) in Q1 2026, closing a stake of 28,712 shares — an estimated $37.6K sold.

Citadel Advisors first reported a position in MNOV in Q2 2014 and held it in 22 quarters. The position peaked at $364K in Q2 2019. 30 funds tracked by Wall St. Rank hold MNOV as of Q1 2026.

  • Citadel Advisors reported no remaining MediciNova position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 28,712 MediciNova shares in Q1 2026, an estimated $37.6K.
  • Citadel Advisors first reported a position in MediciNova in Q2 2014 and held it in 22 quarters.
  • Citadel Advisors's MediciNova position peaked at $364K in Q2 2019.
  • 30 funds tracked by Wall St. Rank held MediciNova as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.